Spots Global Cancer Trial Database for cart
Every month we try and update this database with for cart cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | NCT05672459 | Solid Tumor | Single Injectio... Fludarabine pho... Cyclophosphamid... leukapheresis | 18 Years - | M.D. Anderson Cancer Center | |
| The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) | NCT06160362 | Non-hodgkin Lym... | CART-19 and 20 ... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | Henan Cancer Hospital | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | NCT06267729 | Metastatic Pros... | AZD0754 | 18 Years - 130 Years | AstraZeneca | |
| Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia | NCT03599375 | Leukemia, B-Cel... | CD19-targeted C... | 14 Years - 75 Years | The First Hospital of Jilin University | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) | NCT06160362 | Non-hodgkin Lym... | CART-19 and 20 ... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | Henan Cancer Hospital | |
| Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL | NCT02799550 | Leukemia | allogeneic CART... | 60 Years - | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04884984 | Acute Myeloid L... | anti-CLL1 CART | 6 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Genetically Modified T Cells Against Ovarian Cancer | NCT03184753 | Ovarian Cancer | OC-IgT cells | 18 Years - 65 Years | Shenzhen Geno-Immune Medical Institute | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | NCT04146051 | Myasthenia Grav... | Descartes-08 | 18 Years - | Cartesian Therapeutics | |
| Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia | NCT03599375 | Leukemia, B-Cel... | CD19-targeted C... | 14 Years - 75 Years | The First Hospital of Jilin University | |
| Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | NCT03448978 | Multiple Myelom... | Descartes-08 Fludarabine Cyclophosphamid... | 18 Years - | Cartesian Therapeutics | |
| Retreatment With CTL019/CTL119 | NCT04419909 | Lymphoma, B-Cel... | CD19 redirected... | 18 Years - | University of Pennsylvania | |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | NCT06267729 | Metastatic Pros... | AZD0754 | 18 Years - 130 Years | AstraZeneca | |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | NCT04637503 | Neuroblastoma | GD2, PSMA and C... | 1 Year - 65 Years | Shenzhen Geno-Immune Medical Institute | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| CART Therapy in GUCY2C-positive Digestive Tract Tumors | NCT04652219 | Malignant Neopl... | gucy2c cart cel... | 18 Years - 70 Years | Zhejiang University | |
| A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT04394650 | Multiple Myelom... | CC-98633 | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas | NCT03356782 | Sarcoma Osteoid Sarcoma Ewing Sarcoma | Sarcoma-specifi... | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT04231747 | Lymphoma Non-Ho... Agressive Lymph... Diffuse-large B... | CC-97540 | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Descartes-11 in Multiple Myeloma | NCT03994705 | Multiple Myelom... | Descartes-11 Fludarabine Cyclophosphamid... | 18 Years - | Cartesian Therapeutics | |
| A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT04394650 | Multiple Myelom... | CC-98633 | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Combination Immunotherapy Targeting Sarcomas | NCT04433221 | Sarcoma Osteoid Sarcoma Ewing Sarcoma | Multiple sarcom... | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | NCT04637503 | Neuroblastoma | GD2, PSMA and C... | 1 Year - 65 Years | Shenzhen Geno-Immune Medical Institute | |
| Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL | NCT02799550 | Leukemia | allogeneic CART... | 60 Years - | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) | NCT05169489 | Diffuse Large B... | bbT369 | 18 Years - | 2seventy bio | |
| Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | NCT04287660 | Multiple Myelom... | clarithromycin,... | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
